Stock listing

NYSE:RDY Dr. Reddy's Laboratories Ltd. Stock

US listing (NYSE) of Dr. Reddy's Laboratories Ltd. · home listing NSE:DRREDDY

Follow Dr. Reddy's Laboratories Ltd. into a list and get an email when it puts out news.

Share price · NYSE:RDY

$13.75 USD +0.54 (+4.1%)

Close on Oct 27, 2026

Day range
$13.62 – $13.86 USDOct 27, 2026
Volume
4.58M sharesOct 27, 2026
Market cap
$11.45B USDAt the close on Oct 27, 2026 · price × 833.0M shares outstanding
Dr. Reddy's Laboratories Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NSE:DRREDDY · Home₹1,352.00 INR+7.00 (+0.5%)1,714,059₹1,345.00₹1,363.70₹1,345.00₹1,345.00Close on Oct 30, 2026
NYSE:RDY$13.75 USD+0.54 (+4.1%)4,578,809$13.62$13.86$13.62$13.21Close on Oct 27, 2026
Frankfurt:RDDA€12.40 EUR+0.30 (+2.5%)—€12.40€12.40€12.40€12.10Close on Oct 30, 2026
Ticker
NYSE:RDY
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NYSE
Currency
USD

What changed lately

Calls

Replays

  • Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call

    Fri, Oct 23, 2026 · 10:00 AM ET

    Watch Transcript

  • Dr. Reddy's Laboratories (NSE:DRREDDY) Q1 2027 Earnings Call

    Wed, Jul 22, 2026 · 10:00 AM ET

    Watch Transcript

  • Dr. Reddy's Laboratories (NSE:DRREDDY) Q4 2026 Earnings Call

    Tue, May 12, 2026 · 10:00 AM ET

    Watch Transcript

Latest news

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".

Oct 21, 2026

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".

Oct 7, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Aug 4, 2026

Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026

Aug 1, 2026

Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026

Jul 22, 2026

Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026

Jul 13, 2026

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Jun 29, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Jun 13, 2026

Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)

May 29, 2026

Press Release May 28 2026

May 28, 2026

All Dr. Reddy's Laboratories Ltd. news

Decks

Dr. Reddy's Laboratories Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
33 in the last 12 months · 167 in all · newest Oct 21, 2026 · oldest 2020
Calls
25 calls with a replay · 25 with a transcript · latest Oct 23, 2026
Decks
43 decks · latest Oct 23, 2026

Where Dr. Reddy's Laboratories Ltd. is listed

ListingExchangeCountryCurrency
NSE:DRREDDY · Home listingNSEIndiaINR
NYSE:RDY · This pageNYSEUnited StatesUSD
BSE:DRREDDYBSEIndiaINR
gettex:RDDAgettexGermanyEUR
B3:R1DY34B3BrazilBRL
BOATS:RDYBOATSUnited StatesUSD
Frankfurt:RDDAFrankfurtGermanyEUR
Lang & Schwarz:659157Lang & SchwarzGermanyEUR
LS Exchange:659157LS ExchangeGermanyEUR
Stuttgart:RDDAStuttgartGermanyEUR
Munich:RDDAMunichGermanyEUR
Dusseldorf:RDDADusseldorfGermanyEUR

Log in to ask 6ix AI your own questions about Dr. Reddy's Laboratories Ltd.